A Samsung Bioepis Co. Ltd. spokesperson told BioCentury that FDA extended by three months
FDA extends review of Samsung Bioepis' trastuzumab biosimilar
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
A Samsung Bioepis Co. Ltd. spokesperson told BioCentury that FDA extended by three months